Anti-PSGL-1 antibodies and uses thereof

A method for treating graft-versus-host disease (GVHD), psoriatic arthritis, or ulcerative colitis, the method comprising injecting into to a human subject in need thereof a pharmaceutical composition comprising:

• (i) a monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:
• (a) a light chain comprising a variable light (“VL”) chain region comprising the amino acid sequence of SEQ ID NO:
• 3;
• (b) a heavy chain comprising variable heavy (“VH”) chain region comprising the amino acid sequence of SEQ ID NO:
• 4;
• and
• (c) a human IgG4 constant region which contains a Serine to Proline substitution at amino acid 228 of the heavy chain numbered according to the EU index;
• and
• (ii) a pharmaceutically acceptable carrier,
• wherein, the pharmaceutical composition comprises less than 1% half antibody molecules, wherein upon administration to the subject, the pharmaceutical composition inhibits T-cell mediated inflammation in the subject, and wherein the monoclonal antibody of the pharmaceutical composition administered to the subject is present at a concentration between 0.03 mg/kg and 10 mg/kg.